Abstract: Described herein are companion methods and kits useful for IL-2-based therapies and for mesenchymal stem cell-based therapies.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO as diagnostic and prognostic biomarker assays in renal injuries.

Abstract: The disclosure relates generally to methods and reagents for reducing or shutting down lactation in a non-human mammalian subject. In particular, the disclosure relates to a method of reducing or shutting down lactation in a non-human mammalian subject by administering to the subject by intramammary infusion an agent which activate the OAS2 signalling pathway or induce expression of OAS2. In some examples, the methods and reagents of the disclosure may be useful for the prevention of mastitis in a non-human mammalian subject, such as a dairy cow.

Abstract: Herein described are antibodies to epidermal growth factor receptor (EGER) having an EGER binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.

Abstract: The present disclosure relates to compositions and methods for treating cancer. For example, a modified cell may include a polynucleotide comprising an NFAT promoter, a nucleotide sequence encoding therapeutic agent, and a nucleotide sequence encoding a VHL-interaction domain of HIF1?, wherein the therapeutic agent comprises, for example, IL-12, IL-6, and/or IFN?.

Abstract: Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.

Abstract: Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.

Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

Abstract: Knee pain caused by osteoarthritis is relieved by modifying the shape change of bone(s) underlying articular cartilage, by a method comprising evaluating the bone shape of the patient's joint, injecting the patient with a peptide of SEQ ID No. 1 or applying other therapeutic interventions that can reduce the shape change of the bone(s) underlying articular cartilage, and thereafter evaluating the bone shape of the patient's joint.

Abstract: Disclosed are a method for preparing a porcine-derived interferon-delta 5 (pIFN-?5) and an application of the pIFN-?5, where the method for preparing pIFN-?5 includes the following steps: step S1, obtaining a DNA fragment containing pIFN-?5 gene through reverse transcription-polymerase chain reaction (RT-PCR) amplification by using the total RNA of pretreated porcine small intestinal epithelial cells IPEC-J2; step S2, inserting the DNA fragment containing pIFN-?5 gene into an exogenous expression vector to construct a recombinant expression vector for expressing the pIFN-?5 gene; and step S3, introducing the recombinant expression vector into a suitable host cell, and driving the host cell to express the pIFN-?5 gene to obtain the pIFN-?5. The recombinant pIFN-?5 protein is used to prepare drugs or preparations for inhibiting infection of porcine epidemic diarrhea virus (PEDV), porcine transmissible gastroenteritis virus (TGEV), porcine delta coronavirus (PDCoV) and porcine rotavirus (PRoV).

Abstract: The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.

Abstract: The present disclosure relates to particular subsets of CD4+ and CD8+ T-cells, methods of isolating and generating these cells, compositions comprising these cells, and methods of treatment of a tumor or cancer by administering these cells alone or in combination with each other and/or additional therapies.

Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).

Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.

Abstract: Provided herein are multi-chain chimeric polypeptides that include: (a) a first chimeric polypeptide including a first target-binding domain, a soluble tissue factor domain, and a first domain of a pair of affinity domains; and (b) a second chimeric polypeptide including a second domain of a pair of affinity domains and a second target-binding domain, where the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains. Also provided here are methods of using these multi-chain chimeric polypeptides and nucleic acids encoding these multi-chain chimeric polypeptides.

Abstract: A method of treating sarcopenia comprises immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell. Immunizing a subject includes administering a vaccine that comprises an AGE antigen. Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.

Abstract: The present invention relates to a transgenic CHO cell line in which the BMP receptor gene BMPRIA or BMPRII is knocked out. The BMP type I receptor BMPRIA or BMP type II receptor BMPRII gene which plays an important role in intracellular signal transduction in CHO cells is knocked out to prevent the activation of self concentration control pathway and the signal transduction mediated by BMP in CHO cells, so that the productivity of a target protein to be produced can be improved.

Abstract: This disclosure relates to the field of therapeutic RNAs for treatment of solid tumor cancers.

Abstract: An adenovirus comprising a sequence of formula (I) 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein BY comprises a transgene cassette containing four transgenes, said genes encoding a FAP-Bispecific T cell activator, CXL10, CXL9, and IFN. The disclosure also extends to a pharmaceutical composition comprising the virus, and use of the virus or formulation in treatment.

Abstract: The present disclosure relates to biomarkers of preterm birth, biomarkers of term birth, and methods of use thereof. In particular, the present disclosure provides methods of determining whether a pregnant woman is at an increased risk for premature delivery. The present disclosure further provides methods for decreasing a pregnant woman's risk for premature delivery.